Skip to main content
SpringerLink
Log in

A Case of Hyperthyroidy Developing in “Pegylated-Interferon” Therapy

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kao JH, Chen DS (2002) Global control of hepatitis B virus infection. Lancet Infect Dis 2:395–403

    Article  PubMed  Google Scholar 

  2. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of the Liver Diseases (AASLD) (2004) Chronic hepatitis B: update of recommendations. Hepatology 39:857–861

    Article  PubMed  Google Scholar 

  3. Liaw YF, Leung N, Guan R, et al. (2005) Asian Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25:472–489

    Article  PubMed  Google Scholar 

  4. Dianzani F (1993) Biological basis for the clinical use of interferon. Gut 34:74–76

    Google Scholar 

  5. Lok AS, Lai CL, Wu PC, Leung EKY (1988) Long-term follow-up in a randomised controlled trial of recombinant alpha 2 interferon in Chinese patients with chronic hepatitis B infection. Lancet 2:298–302

    Article  PubMed  CAS  Google Scholar 

  6. Wong DKH, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B and antigen-positive hepatitis B: meta-analysis. Ann Intern Med 119:312–323

    PubMed  CAS  Google Scholar 

  7. Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26:112–121

    Google Scholar 

  8. Dolar E (2002) Viral diseases of liver: Hepatitis C virus infection. Clin Liver Dis 1st ed.:247–283

    Google Scholar 

  9. Abuchowski A, van Es T, Palczuk NC, Davis FF (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578–3581

    PubMed  CAS  Google Scholar 

  10. Glue P, Fang JW, Rouzier Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S (2000) PEG-interferon alpha-2b: pharmocokinetics, pharmocodynamics, safety and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68:556–567

    CAS  Google Scholar 

  11. Trask PC, Esper P, Riba M, Redman B (2000) Psychiatric side effects of interferone therapy: prevalence, proposed mecahanisms, and future directions. J Clin Oncol 18:2316– 2326

    PubMed  CAS  Google Scholar 

  12. Monzani F, Caraccio N, Dardano A, Ferrannini E (2004) Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 3:199–210

    Article  PubMed  CAS  Google Scholar 

  13. Wong V, Fu AX, George J, Cheung NW (2002) Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol 56:793–798

    Article  CAS  Google Scholar 

  14. Doi F, Kakizaki S, Takagi H, Murakami M, Sohara N, Otsuka T, Abe T, Mori M (2005) Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 25:242–246

    Article  PubMed  Google Scholar 

  15. Koh LK, Greenspan FS, Yeo PP (1997) Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7:891–896

    Article  PubMed  CAS  Google Scholar 

  16. Ozet A, Ozet G, Caliskaner Z, Komurcu S, Ozturk B (1997) Development of hyperthyroidysm during long term interferon therapy in a patient with chronic myelogenous leukemia: case report. Endocr J 4:715–717

    Google Scholar 

  17. Pichert G, Jost LM, Zobeli L, Odermatt B, Pedia G, Stahel RA (1990) Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer 62:100–104

    PubMed  CAS  Google Scholar 

  18. Fernandez Diez S, Rodriguez Agullo JL, Cascudo Rielo MJ, Navarro Angulo N, Diaz-Rubio M (2002) Interferon-alfa induced transient thyroid dysfunction in hepatitis C. Rev Esp Enferm Dig 94:159–163

    PubMed  CAS  Google Scholar 

  19. Parana R, Cruz M, Lyra L, Cruz T (2000) Subakut thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J Viral Hepat 7:393–395

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Faculty of Medicine, Harran University, Bahcelievler Mah. Sema Apt. A Blok No. 8, Sanliurfa, 63200, Turkey

    Mehmet Aslan, Yasar Nazlıgul & Nevin Yılmaz

  2. Department of Clinical Chemistry, Faculty of Medicine, Harran University, Sanliurfa, Turkey

    Nurten Aksoy

Authors
  1. Mehmet Aslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasar Nazlıgul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nurten Aksoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nevin Yılmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Aslan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aslan, M., Nazlıgul, Y., Aksoy, N. et al. A Case of Hyperthyroidy Developing in “Pegylated-Interferon” Therapy. Dig Dis Sci 52, 1194–1196 (2007). https://doi.org/10.1007/s10620-006-9318-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-006-9318-7

Keywords

Search

Navigation